Literature DB >> 33261052

Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial.

Katharina J Wenger1,2,3,4, Marlies Wagner1,2,3,4, Patrick N Harter2,3,4,5, Kea Franz2,3,4,6, Jörg Bojunga4,7, Emmanouil Fokas2,3,4,8, Detlef Imhoff2,3,4,8, Claus Rödel2,3,4,8, Johannes Rieger9,10, Elke Hattingen1,2,3,4, Joachim P Steinbach2,3,4,9, Ulrich Pilatus1,2,3,4, Martin Voss2,3,4,9.   

Abstract

Background: The ERGO2 (Ernaehrungsumstellung bei Patienten mit Rezidiv eines Glioblastoms) MR-spectroscopic imaging (MRSI) subtrial investigated metabolism in patients randomized to calorically restricted ketogenic diet/intermittent fasting (crKD-IF) versus standard diet (SD) in addition to re-irradiation (RT) for recurrent malignant glioma. Intracerebral concentrations of ketone bodies (KB), intracellular pH (pHi), and adenosine triphosphate (ATP) were non-invasively determined.
Methods: 50 patients were randomized (1:1): Group A keeping a crKD-IF for nine days, and Group B a SD. RT was performed on day 4-8. Twenty-three patients received an extended MRSI-protocol (1H decoupled 31P MRSI with 3D chemical shift imaging (CSI) and 2D 1H point-resolved spectroscopy (PRESS)) at a 3T scanner at baseline and on day 6. Voxels were selected from the area of recurrent tumor and contralateral hemisphere. Spectra were analyzed with LCModel, adding simulated signals of 3-hydroxybutyrate (βOHB), acetone (Acn) and acetoacetate (AcAc) to the standard basis set.
Results: Acn was the only reliably MRSI-detectable KB within tumor tissue and/or normal appearing white matter (NAWM). It was detected in 4/11 patients in Group A and in 0/8 patients in Group B. MRSI results showed no significant depletion of ATP in tumor tissue of patients at day 6 during crKD-IF, even though there were a significant difference in ketone serum levels between Group A and B at day 6 and a decline in fasting glucose in Group A from baseline to day 6. The tumor specific alkaline pHi was maintained. Conclusions: Our metabolic findings suggest that tumor cells maintain energy homeostasis even with reduced serum glucose levels and may generate additional ATP through other sources.

Entities:  

Keywords:  ATP; MR-spectroscopy; fasting; glioblastoma; ketogenic diet; ketone body

Year:  2020        PMID: 33261052     DOI: 10.3390/cancers12123549

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  Prognostic Biomarker KIF18A and Its Correlations With Immune Infiltrates and Mitosis in Glioma.

Authors:  Bing-Yan Tao; Yu-Yang Liu; Hong-Yu Liu; Ze-Han Zhang; Yun-Qian Guan; Hui Wang; Ying Shi; Jun Zhang
Journal:  Front Genet       Date:  2022-05-03       Impact factor: 4.772

2.  Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial.

Authors:  Joachim P Steinbach; Claus Rödel; Johannes Rieger; Martin Voss; Katharina J Wenger; Nina von Mettenheim; Jörg Bojunga; Manuela Vetter; Bianca Diehl; Kea Franz; Ruediger Gerlach; Michael W Ronellenfitsch; Patrick N Harter; Elke Hattingen
Journal:  Eur J Nutr       Date:  2021-09-06       Impact factor: 5.614

3.  The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.

Authors:  Rodrigo Javier; Wenxia Wang; Michael Drumm; Kathleen McCortney; Jann N Sarkaria; Craig Horbinski
Journal:  PLoS One       Date:  2022-02-08       Impact factor: 3.240

4.  Effect of Ketogenic Diets on Body Composition and Metabolic Parameters of Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Haobin Zhao; Han Jin; Junfang Xian; Zhifu Zhang; Junling Shi; Xiaosu Bai
Journal:  Nutrients       Date:  2022-10-08       Impact factor: 6.706

5.  Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma.

Authors:  Karisa C Schreck; Fang-Chi Hsu; Adam Berrington; Bobbie Henry-Barron; Diane Vizthum; Lindsay Blair; Eric H Kossoff; Linda Easter; Christopher T Whitlow; Peter B Barker; Mackenzie C Cervenka; Jaishri O Blakeley; Roy E Strowd
Journal:  Neurology       Date:  2021-07-07       Impact factor: 11.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.